Scholar Rock Holding Corporation (SRRK) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Scholar Rock Holding Corporation (SRRK) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
SRRK - Scholar Rock Holding Corporation
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$64.40
DETAILS
HIGH:
$76.00
LOW:
$55.00
MEDIAN:
$64.00
CONSENSUS:
$64.40
UPSIDE:
15.68%
Stock News
Scholar Rock: Manufacturing Noise Obscures A Muscle-Targeted Franchise
Scholar Rock is positioned to launch apitegromab as the first muscle-targeted therapy for SMA, pending FDA approval by September 30, 2026. Manufacturing setbacks were production-based, not due to drug efficacy or safety; the alternate fill-finish facility mitigates approval risk but does not eliminate it. SAPPHIRE trial data support apitegromab's add-on value in SMA, showing statistically significant motor function gains over placebo for nonambulatory patients.
Scholar Rock Receives FDA Fast Track Designation for Apitegromab Facioscapulohumeral Muscular Dystrophy (FSHD) Program as Participant Dosing Commences in Phase 2 FORGE Trial
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseases by applying its world-leading platform in myostatin biology, today announced that the FDA has granted Fast Track and Orphan Drug designations to apitegromab for the treatment of people living with FSHD. In addition, the Company announced that participant dosing is underway in the Phase 2 FORGE c.
Beaconlight Capital LLC Makes New Investment in Scholar Rock Holding Corporation $SRRK
Beaconlight Capital LLC purchased a new stake in shares of Scholar Rock Holding Corporation (NASDAQ: SRRK) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 87,893 shares of the company's stock, valued at approximately $4,834,000. Scholar Rock makes up about 1.7%
9,494,084 Shares in Scholar Rock Holding Corporation $SRRK Purchased by BlackRock Inc.
BlackRock Inc. acquired a new position in shares of Scholar Rock Holding Corporation (NASDAQ: SRRK) in the undefined quarter, according to its most recent filing with the SEC. The fund acquired 9,494,084 shares of the company's stock, valued at approximately $522,175,000. BlackRock Inc. owned approximately 7.92% of Scholar Rock at the end of
Scholar Rock Provides Update on Global Apitegromab Regulatory Progress Across U.S., Europe, and Japan
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseases by applying its world-leading platform in myostatin biology, today announced it has successfully removed Catalent Indiana LLC (part of Novo Nordisk) as a commercial fill-finish facility from its apitegromab Biologics License Application (BLA) for the treatment of spinal muscular atrophy (SMA) in.
Scholar Rock Eyes Sept. 30 FDA Decision for SMA Drug Apitegromab
Scholar Rock NASDAQ: SRRK CEO David Hallal said the company is preparing for a September 30 FDA decision date for apitegromab, its investigational treatment for spinal muscular atrophy, or SMA, following a resubmitted biologics license application supported by an alternate fill-finish manufacturing facility.
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”) today announced that the company granted inducement equity awards covering an aggregate of 51,947 shares of its common stock to twelve newly hired employees, consisting of inducement stock options to purchase an aggregate of 14,889 shares of common stock and inducement restricted stock units, covering an aggregate of 37,058 shares of its common stock. The awards are subject to all terms and conditions and other provis.
Scholar Rock drops Catalent facility from marketing application for muscle weakness drug
Scholar Rock said on Friday it would remove Catalent's Indiana manufacturing facility from its application seeking FDA approval for a rare neuromuscular disease drug.
Scholar Rock Announces FDA Review of Apitegromab Biologics License Application (BLA) for Spinal Muscular Atrophy (SMA) to Progress with Second Fill-Finish Facility; Approval Decision Anticipated by September 30, 2026 Action Date
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseases by applying its world-leading platform in myostatin biology, today announced that the FDA review of the apitegromab Biologics License Application (BLA) for the treatment of children and adults with spinal muscular atrophy (SMA) is progressing with the Company's second fill-finish facility. The B.
Scholar Rock Q2 Earnings Call Highlights
Scholar Rock NASDAQ: SRRK said its resubmitted biologics license application for apitegromab remains on track for a U.S. Food and Drug Administration decision by its Sept. 30 PDUFA date, as the company prepares for a potential launch of the muscle-targeted treatment for spinal muscular atrophy, or SMA.
Scholar Rock Holding Corporation (SRRK) Q2 2026 Earnings Call Transcript
Scholar Rock Holding Corporation (SRRK) Q2 2026 Earnings Call Transcript
Scholar Rock Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular d
Scholar Rock Reports Second Quarter 2026 Financial Results and Recent Business Highlights
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology, today reported financial results for the second quarter ended June 30, 2026, and provided an update on recent company developments. “We are on the threshold of securing the world's first ever regulatory approval of a myostatin inhibitor, whi.
Scholar Rock to Present at the Canaccord Genuity 46th Annual Growth Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology, today announced that management will present at the Canaccord Genuity 46th Annual Growth Conference in Boston, MA on Wednesday, August 12, 2026 at 1:30 p.m. ET. A live webcast of the ev.
Kuehn Law Encourages Investors of Scholar Rock Holding Corp to Contact Law Firm
Kuehn Law Encourages Investors of Scholar Rock Holding Corp to Contact Law Firm PR Newswire NEW YORK, July 28, 202
Kuehn Law Encourages Investors of Scholar Rock Holding Corp to Contact Law Firm
NEW YORK, July 28, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Scholar Rock Holding Corp (NASDAQ: SRRK) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing.
Kuehn Law Encourages Investors of Scholar Rock Holding Corp to Contact Law Firm
NEW YORK, July 20, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Scholar Rock Holding Corp (NASDAQ: SRRK) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance reforms.
Scholar Rock says EU opinion on SMA drug may be pushed to later in 2026
Scholar Rock said on Monday a European Union opinion on its experimental spinal muscular atrophy treatment could be pushed to later this year, as regulators await the U.S. FDA's classification of a manufacturing facility included in the drug developer's European filing.
Scholar Rock Provides Update on Timing of Committee for Medicinal Products for Human Use (CHMP) Opinion for Apitegromab Marketing Authorisation Application (MAA) for Spinal Muscular Atrophy (SMA)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseases by applying its world-leading platform in myostatin biology, today provided an update on the anticipated timing of a Committee for Medicinal Products for Human Use (CHMP) opinion for the apitegromab marketing authorisation application (MAA) for children and adults with spinal muscular atrophy (S.
Price Targets
Scholar Rock price target raised to $64 from $58 at Wedbush
$64.00
(was $55.97)
Wedbush
Scholar Rock price target raised to $76 from $70 at BMO Capital
$76.00
(was $52.18)
BMO Capital
Scholar Rock price target raised to $55 from $53 at Barclays
$55.00
(was $46.45)
Barclays
Scholar Rock price target raised to $65 from $58 at H.C. Wainwright
$65.00
(was $46.45)
H.C. Wainwright
Scholar Rock initiated with a Buy at Canaccord
$62.00
(was $47.80)
Canaccord Genuity
'We are incrementally positive on Scholar Rock (SRRK) Shares'; PT Raised at Piper Sandler
$58.00
(was $44.85)
Allison Bratzel
·
Piper Sandler
Scholar Rock (SRRK) PT Raised to $53 at Barclays
$53.00
(was $44.31)
Etzer Darout
·
Barclays
Scholar Rock (SRRK) PT Raised to $55 at Truist Securities
$55.00
(was $44.31)
Srikripa Devarakonda
·
Truist Financial
Scholar Rock price target raised to $58 from $44 at H.C. Wainwright
$58.00
(was $44.29)
Andres Maldonado
·
H.C. Wainwright
UBS Starts Scholar Rock (SRRK) at Buy
$60.00
(was $41.31)
Michael Yee
·
UBS
Scholar Rock price target raised to $52 from $45 at Barclays
$52.00
(was $44.32)
Etzer Darout
·
Barclays
Scholar Rock price target raised to $50 from $45 at BMO Capital
$50.00
(was $37.41)
BMO Capital
Scholar Rock price target lowered to $51 from $52 at Piper Sandler
$51.00
(was $33.75)
Allison Bratzel
·
Piper Sandler
Scholar Rock price target lowered to $44 from $45 at Barclays
$44.00
(was $33.39)
Etzer Darout
·
Barclays
Scholar Rock initiated with an Overweight at Barclays
$45.00
(was $32.34)
Barclays
Scholar Rock assumed with a Strong Buy at Raymond James
$53.00
(was $37.27)
Raymond James
Scholar Rock (SRRK) PT Raised to $39 at BMO Capital
$39.00
(was $26.97)
Etzer Darout
·
BMO Capital
Scholar Rock (SRRK) PT Raised to $42 at Piper Sandler
$42.00
(was $28.52)
Allison Bratzel
·
Piper Sandler
Scholar Rock (SRRK) PT Raised to $38 at BMO Capital
$38.00
(was $25.27)
Etzer Darout
·
BMO Capital
Scholar Rock price target raised to $31 from $29 at BMO Capital
$31.00
(was $9.39)
Etzer Darout
·
BMO Capital